Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Dietary Bioactive Compounds and Breast Cancer
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Dietary Bioactive Compounds and Breast Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: closed (1 September 2021) | Viewed by 23123

Special Issue Editors

Dr. Antonio González-Sarrías

E-Mail Website
Guest Editor
Laboratory of Food and Health, Food and Technology Department, National Council for Scientific Research (CEBAS-CSIC), Murcia, Spain
Interests: food and health; bioactive compounds; polyphenols; cell culture and animal models; clinical trials; cardiovascular; cancer; inflammation
Special Issues, Collections and Topics in MDPI journals
Dr. Juan Antonio Giménez-Bastida

E-Mail Website
Guest Editor
Laboratory of Food and Helath, Research Group on Quality, Safety and Bioactivity of Plant Foods, Department Food Science and Technology, CEBAS-CSIC, P.O. Box 164, Campus de Espinardo, 30100 Murcia, Spain
Interests: polyphenols; in vitro; in vivo; pharmacology; eicosanoids; inflammation; cardiovascular; health; bioactive molecules
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Breast cancer is the most common occurring cancer and one of the leading causes of cancer-related death in women worldwide. Over 80% of cases are non-hereditary, and therefore, modifiable extrinsic factors related to lifestyle, including dietary habits, play a key role in its prevention. Plant foodstuff is the most important source of bioactive compounds, including polyphenols, carotenoids, phytosterols and others, that have been reported to exert anticancer effects by playing a broad range of pleiotropic multi-targeted activities on breast cancer cells and animal models. Although many epidemiological and observational studies have inversely correlated the fruits and vegetables consumption with breast cancer incidence, the involvement of their phytochemicals remains still contradictory. Over the past decades, wrong approaches without considering their bioavailability and metabolism have been behind the current gap between preclinical and clinical research.

Therefore, this Special Issue of International Journal of Molecular Sciences will publish original research and review papers on the chemopreventive and/or chemosensitization effects to breast cancer of dietary bioactive compounds and/or derived metabolites using physiologically relevant preclinical (cell and animal models) and clinical approaches, that could elucidate if they are responsible for the effects attributed to plant-based foods.

Dr. Antonio González-Sarrías
Dr. Juan Antonio Giménez-Bastida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • chemoprevention
  • plant foods
  • phytochemicals
  • phytoestrogens
  • polyphenols
  • bioavailability studies
  • clinical trials
  • animal and cellular studies
  • anti-cancer mechanisms

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 213 KiB  
Editorial
Dietary Bioactive Compounds and Breast Cancer
by Juan Antonio Giménez-Bastida and Antonio González-Sarrías
Int. J. Mol. Sci. 2023, 24(11), 9731; https://doi.org/10.3390/ijms24119731 - 04 Jun 2023
Cited by 1 | Viewed by 989
Abstract
Cancer is among the most serious health problems and the second leading cause of death globally, affecting millions of people worldwide [...] Full article
(This article belongs to the Special Issue Dietary Bioactive Compounds and Breast Cancer)

Research

Jump to: Editorial, Review

16 pages, 3460 KiB  
Article
Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis
by Rashidra R. Walker, Jankiben R. Patel, Akash Gupta, A. Michael Davidson, Christopher C. Williams, Florastina Payton-Stewart, Stephen M. Boué, Matthew E. Burow, Rahul Khupse and Syreeta L. Tilghman
Int. J. Mol. Sci. 2022, 23(5), 2887; https://doi.org/10.3390/ijms23052887 - 07 Mar 2022
Cited by 7 | Viewed by 2088
Abstract
Aromatase inhibitors (AIs) are standard treatment for estrogen-dependent postmenopausal breast tumors; however, resistance develops leading to tumor relapse and metastasis. We previously demonstrated that glyceollin inhibits proliferation, survival, and migration of hormone-independent letrozole-resistant breast cancer. Since many AI-resistant tumors remain hormone-dependent, identifying distinctions [...] Read more.
Aromatase inhibitors (AIs) are standard treatment for estrogen-dependent postmenopausal breast tumors; however, resistance develops leading to tumor relapse and metastasis. We previously demonstrated that glyceollin inhibits proliferation, survival, and migration of hormone-independent letrozole-resistant breast cancer. Since many AI-resistant tumors remain hormone-dependent, identifying distinctions between estrogen-receptor-positive (ER+) and ER-negative (ER-) AI-resistant tumor response to therapy is critical. We hypothesize that treating ER+ letrozole-resistant T47D breast cancer cells (T47DaromLR) with a combination of 10 μM glyceollin and 0.5 μM lapatinib (a dual EGFR/HER2 inhibitor) will decrease cell proliferation through induction of apoptosis. The T47DaromLR cells were found to overexpress HER2 and MAPK while maintaining aromatase and ER levels compared to their letrozole-sensitive (T47Darom) counterparts. In the absence of estrogen stimulation, glyceollin ± lapatinib had no effect on the proliferation of the T47Darom cells, while glyceollin treatment caused 46% reduction in the proliferation of T47DaromLR cells, which was further diminished when combined with lapatinib. While neither agent influenced cell migration, glyceollin and lapatinib reduced S and G2/M phase cell entry and exclusively induced apoptosis by 1.29-fold in the T47DaromLR cells. Taken together, these results suggest that glyceollins and lapatinib may have potential as a novel combination therapeutic approach for hormone-dependent, letrozole-resistant tumors. Full article
(This article belongs to the Special Issue Dietary Bioactive Compounds and Breast Cancer)
►▼ Show Figures

Figure 1

18 pages, 4160 KiB  
Article
Comparison of the Effects of Resveratrol and Its Derivatives on the Radiation Response of MCF-7 Breast Cancer Cells
by Dominika Komorowska, Agnieszka Gajewska, Paweł Hikisz, Grzegorz Bartosz and Aleksandra Rodacka
Int. J. Mol. Sci. 2021, 22(17), 9511; https://doi.org/10.3390/ijms22179511 - 01 Sep 2021
Cited by 9 | Viewed by 2747
Abstract
Radiotherapy is among the most important methods for breast cancer treatment. However, this method’s effectiveness is limited by radioresistance. The aim of this study was to investigate whether the stilbene derivatives piceid, resveratrol, and piceatannol have a radiosensitising effect on breast cancer cells [...] Read more.
Radiotherapy is among the most important methods for breast cancer treatment. However, this method’s effectiveness is limited by radioresistance. The aim of this study was to investigate whether the stilbene derivatives piceid, resveratrol, and piceatannol have a radiosensitising effect on breast cancer cells (MCF-7). The conducted research enabled us to determine which of the tested compounds has the greatest potential in sensitising cells to ionising radiation (IR). Among the stilbene derivatives, resveratrol significantly increased the effect of IR. Resveratrol and IR used in combination had a higher cytotoxic effect on MCF-7 cells than using piceatannol, piceid, or radiation alone. This was due to a significant decrease in the activity of antioxidant enzymes, which resulted in the accumulation of formed reactive oxygen species (ROS). The effect of resveratrol and IR enhanced the expression of apoptotic genes, such as Bax, p53, and caspase 8, leading to apoptosis. Full article
(This article belongs to the Special Issue Dietary Bioactive Compounds and Breast Cancer)
►▼ Show Figures

Figure 1

16 pages, 2764 KiB  
Article
Chrysoeriol Prevents TNFα-Induced CYP19 Gene Expression via EGR-1 Downregulation in MCF7 Breast Cancer Cells
by Dong Yeong Min, Euitaek Jung, Sung Shin Ahn, Young Han Lee, Yoongho Lim and Soon Young Shin
Int. J. Mol. Sci. 2020, 21(20), 7523; https://doi.org/10.3390/ijms21207523 - 12 Oct 2020
Cited by 11 | Viewed by 2991
Abstract
Estrogen overproduction is closely associated with the development of estrogen receptor-positive breast cancer. Aromatase, encoded by the cytochrome P450 19 (CYP19) gene, regulates estrogen biosynthesis. This study aimed to identify active flavones that inhibit CYP19 expression and to explore the underlying mechanisms. CYP19 [...] Read more.
Estrogen overproduction is closely associated with the development of estrogen receptor-positive breast cancer. Aromatase, encoded by the cytochrome P450 19 (CYP19) gene, regulates estrogen biosynthesis. This study aimed to identify active flavones that inhibit CYP19 expression and to explore the underlying mechanisms. CYP19 expression was evaluated using reverse transcription PCR, quantitative real-time PCR, and immunoblot analysis. The role of transcription factor early growth response gene 1 (EGR-1) in CYP19 expression was assessed using the short-hairpin RNA (shRNA)-mediated knockdown of EGR-1 expression in estrogen receptor-positive MCF-7 breast cancer cells. We screened 39 flavonoids containing 26 flavones and 13 flavanones using the EGR1 promoter reporter activity assay and observed that chrysoeriol exerted the highest inhibitory activity on tumor necrosis factor alpha (TNFα)-induced EGR-1 expression. We further characterized and demonstrated that chrysoeriol inhibits TNFα-induced CYP19 expression through inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated EGR-1 expression. Chrysoeriol may be beneficial as a dietary supplement for the prevention of estrogen receptor-positive breast cancer, or as a chemotherapeutic adjuvant in the treatment of this condition. Full article
(This article belongs to the Special Issue Dietary Bioactive Compounds and Breast Cancer)
►▼ Show Figures

Graphical abstract

Review

Jump to: Editorial, Research

19 pages, 15719 KiB  
Review
Impact of Stilbenes as Epigenetic Modulators of Breast Cancer Risk and Associated Biomarkers
by Sebanti Ganguly, Itika Arora and Trygve O. Tollefsbol
Int. J. Mol. Sci. 2021, 22(18), 10033; https://doi.org/10.3390/ijms221810033 - 17 Sep 2021
Cited by 6 | Viewed by 2530
Abstract
With the recent advancement of genetic screening for testing susceptibility to mammary oncogenesis in women, the relevance of the gene−environment interaction has become progressively apparent in the context of aberrant gene expressions. Fetal exposure to external stressors, hormones, and nutrients, along with the [...] Read more.
With the recent advancement of genetic screening for testing susceptibility to mammary oncogenesis in women, the relevance of the gene−environment interaction has become progressively apparent in the context of aberrant gene expressions. Fetal exposure to external stressors, hormones, and nutrients, along with the inherited genome, impact its traits, including cancer susceptibility. Currently, there is increasing interest in the role of epigenetic biomarkers such as genomic methylation signatures, plasma microRNAs, and alterations in cell-signaling pathways in the diagnosis and primary prevention of breast cancer, as well as its prognosis. Polyphenols like natural stilbenes have been shown to be effective in chemoprevention by exerting cytotoxic effects that can stall cell proliferation. Besides possessing antioxidant properties against the DNA-damaging effects of reactive oxygen species, stilbenes have also been observed to modulate cell-signaling pathways. With the increasing trend of early-life screening for hereditary breast cancer risks, the potency of different phytochemicals in harnessing the epigenetic biomarkers of breast cancer risk demand more investigation. This review will explore means of exploiting the abilities of stilbenes in altering the underlying factors that influence breast cancer risk, as well as the appearance of associated biomarkers. Full article
(This article belongs to the Special Issue Dietary Bioactive Compounds and Breast Cancer)
►▼ Show Figures

Figure 1

14 pages, 1534 KiB  
Review
Why Vitamin C Could Be an Excellent Complementary Remedy to Conventional Therapies for Breast Cancer
by Michela Codini
Int. J. Mol. Sci. 2020, 21(21), 8397; https://doi.org/10.3390/ijms21218397 - 09 Nov 2020
Cited by 12 | Viewed by 5111
Abstract
The most frequent cancer in women is breast cancer, which is a major cause of death. Currently, there are many pharmacological therapies that have made possible the cure and resolution of this tumor. However, these therapies are accompanied by numerous collateral effects that [...] Read more.
The most frequent cancer in women is breast cancer, which is a major cause of death. Currently, there are many pharmacological therapies that have made possible the cure and resolution of this tumor. However, these therapies are accompanied by numerous collateral effects that influence the quality of life (QoL) of the patients to varying degrees. For this reason, attention is turning to the use of complementary medicine to improve QoL. In particular, there are increased trials of intravenous injection of vitamin C at high doses to enhance the antitumor activity of drugs and/or decrease their side effects. This review intends to underline the anticancer mechanisms of vitamin C that could explain its efficacy for treating breast cancer, and why the use of vitamin C at high doses could help patients with breast cancer to enhance the efficacy of pharmacological therapies and/or decrease their side effects. Full article
(This article belongs to the Special Issue Dietary Bioactive Compounds and Breast Cancer)
►▼ Show Figures

Figure 1

33 pages, 356 KiB  
Review
Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives
by María Ángeles Ávila-Gálvez, Juan Antonio Giménez-Bastida, Juan Carlos Espín and Antonio González-Sarrías
Int. J. Mol. Sci. 2020, 21(16), 5718; https://doi.org/10.3390/ijms21165718 - 10 Aug 2020
Cited by 42 | Viewed by 5050
Abstract
Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death in adult women worldwide. Over 85% of BC cases are non-hereditary, caused by modifiable extrinsic factors related to lifestyle, including dietary habits, which play a crucial role in [...] Read more.
Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death in adult women worldwide. Over 85% of BC cases are non-hereditary, caused by modifiable extrinsic factors related to lifestyle, including dietary habits, which play a crucial role in cancer prevention. Although many epidemiological and observational studies have inversely correlated the fruit and vegetable consumption with the BC incidence, the involvement of their phenolic content in this correlation remains contradictory. During decades, wrong approaches that did not consider the bioavailability, metabolism, and breast tissue distribution of dietary phenolics persist behind the large currently existing gap between preclinical and clinical research. In the present review, we provide comprehensive preclinical and clinical evidence according to physiologically relevant in vitro and in vivo studies. Some dietary phenolics such as resveratrol (RSV), quercetin, isoflavones, epigallocatechin gallate (EGCG), lignans, and curcumin are gaining attention for their chemopreventive properties in preclinical research. However, the clinical evidence of dietary phenolics as BC chemopreventive compounds is still inconclusive. Therefore, the only way to validate promising preclinical results is to conduct clinical trials in BC patients. In this regard, future perspectives on dietary phenolics and BC research are also critically discussed. Full article
(This article belongs to the Special Issue Dietary Bioactive Compounds and Breast Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop